Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020 – New research available at RnRMarketResearch.com
Over the years, the nuclear medicine/radiopharmaceuticals market has witnessed various advancements in radiopharmaceuticals. The global nuclear medicine/radiopharmaceuticals market is growing due to the increasing number of radioisotope approvals for different clinical indications. Tc-99m and F-18 are estimated to be the highest contributors to the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, Ra-223, I-131, and Y-90 are estimated to be the highest contributors for the nuclear medicine/radiopharmaceuticals therapeutics market in 2015. In 2015, the diagnostics segment accounted for the largest share of the nuclear medicine market, by type; the SPECT segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals diagnostics market; whereas, the beta emitters segment accounted for the largest share of the nuclear medicine/radiopharmaceuticals therapeutics market.
Browse 113 market data tables & 55 figures spread through 230 pages and in-depth TOC on “Nuclear Medicine Market" at http://www.rnrmarketresearch.com/nuclear-medicineradiopharmaceuticals-spectpet-radioisotopes-technetium-f-18-betaalpha-radiation-therapy-i131-y-90-applications-canceroncology-cardiac-stable-isotopes-deuterium-market-report.html .
In 2015, North America accounted for the largest share of the nuclear medicine/radiopharmaceuticals market, followed by Asia-Pacific, Europe, and the Rest of the World (RoW). In the coming years, the Asia-Pacific region is expected to witness the highest growth rate for the nuclear medicine/radiopharmaceuticals market, with an emphasis on India, China, Japan, and Australia. These countries are expected to be lucrative markets forthe manufacturers of radiopharmaceuticals. The global nuclear medicine/radiopharmaceuticals market witnesses high-competitive intensity as there are several large and small firms with similar product offerings.
For more inquiry on thisr report @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=88290 .
These companies adopt various strategies (agreements, contracts, partnerships, expansions, acquisitions, market development, new product launches, marketing and promotional activities, technological enhancements, and website launches) to increase their market shares and to establish a strong foothold in the global market.
Reasons to Buy the Report:
From an insight perspective, this research report focuses on various levels of analysis such as industry analysis (industry trends, value chain analysis,supply chain analysis, and Porter’s five forces model), market share analysis of top ten players, and company profiles, which together comprise and discuss basic views on the competitive landscape, emerging and high-growth segments of the electrophysiology market, high-growth regions and countries and their respectiv edrivers, restraints, challenges, and opportunities.
Priced at $4650 for a single user PDF, a discount on “Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2020” research report can be requested at http://www.rnrmarketresearch.com/contacts/discount?rname=88290 .
(Contact us @ email@example.com / + 1 888 391 5441)
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.